Hepatic Fas protein expression might be a predictive factor for hepatocellular carcinoma development in patients with chronic hepatitis C undergoing interferon therapy

Journal of Clinical Gastroenterology

Volumn 34, Issue 3, 2002, Pages 263-267

  Hirashima, Noboru ^a   Matsumoto, Yoshihiro ^a   Ohono, Tomoyoshi ^a   Kimura, Yoshihide ^a   Hasegawa, Izumi ^a   Ueda, Ryuzo ^a  

^a CHUKYO HOSPITAL   (Japan)

Author keywords

Chronic hepatitis C; Fas expression; Hepatic fibrosis; Hepatocellular carcinoma; Interferon therapy

Indexed keywords

FAS ANTIGEN; INTERFERON;

ADULT; ARTICLE; CONTROLLED STUDY; ERADICATION THERAPY; FEMALE; FOLLOW UP; HEPATITIS C; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER BIOPSY; LIVER CELL CARCINOMA; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RISK FACTOR;

ADULT; AGED; ANTIVIRAL AGENTS; CARCINOMA, HEPATOCELLULAR; FEMALE; FOLLOW-UP STUDIES; GENE EXPRESSION; HEPATITIS C, CHRONIC; HUMANS; INTERFERONS; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; OLIGOPEPTIDES; PREDICTIVE VALUE OF TESTS; RISK FACTORS;

EID: 0036182891     PISSN: 01920790     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004836-200203000-00014     Document Type: Article

References (37)

1. Randomised trial of interferon α2b plus ribavirin for 48 weeks or for 24 weeks versus interferon α2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus
2. Treatment of chronic non-A, non-B hepatitis with recombinant human alpha interferon; a preliminary report
3. Treatment of chronic hepatitis C with recombinant interferon alpha: A multicenter randomized, controlled trial
4. Recombinant interferon alpha therapy for chronic hepatitis C: A randomized, double-blind, placebo-controlled trial
5. Quantitative analysis of hepatitis C virus RNA in serum during interferon alfa therapy
6. Hepatitis C virus serotype responds more favorably to interferon-α therapy
7. Meta-analysis of interferon randomized trials in the treatment of viral hepatitis
8. Risk factors for hepatocellular carcinoma and its incidence after interferon treatment in patients with chronic hepatitis C
9. Cytotoxic T cells and viral hepatitis
10. Fas and perform pathways as major mechanisms of T cell-mediated cytotoxicity
11. Immunohistochemical detection of Fas antigen in liver tissue of patients with chronic hepatitis C
12. The 5′-terminal sequence of the hepatitis C virus genome
13. Significance of specific antibody assay for genotyping of hepatitis C virus
14. The nomenclature of chronic active hepatitis: An obituary
15. Interrelationship of blood transfusion, non-A, non-B hepatitis and hepatocellular carcinoma: Analysis by detection of antibody to hepatitis C virus
16. Long-term mortality after transfusion-associated non-A, non-B hepatitis
17. Clinical outcomes after transfusion-associated hepatitis C
18. Natural history of liver fibrosis progression in patients with chronic hepatitis C
19. Ability of prolonged interferon treatment to suppress relapse after cessation of therapy in patients with chronic hepatitis C: A multicenter randomized controlled trial
20. Improvement of liver fibrosis in chronic hepatitis C patients treated with natural interferon alpha
21. Randomized trial of effects of interferon-a on incidence of hepatocellular carcinoma in chronic hepatitis C with cirrhosis
22. Hepatitis C virus genotype and RNA titer in the progression of type C chronic liver disease
23. Detection of hepatitis C virus by polymerase chain reaction and response to interferon therapy: Relationship to genotypes of hepatitis C virus
24. Development of hepatocellular carcinoma in a patient with chronic hepatitis C infection after a complete and sustained response to interferon-a
25. Prospective study of early detection of hepatocellular carcinoma in patients with cirrhosis
26. A multivariate analysis of risk factors for hepatocellular carcinogenesis: A prospective observation of 795 patients with viral and alcoholic cirrhosis
27. Incidence of hepatocellular carcinoma in chronic hepatitis B and C. A prospective study of 251 patients
28. Loss of heterozygosity in liver tumors
29. Association of cumulative allelic losses with tumor aggressiveness in hepatocellular carcinoma
30. High-level expression of hepatitis B virus HBx gene and hepatocarcinogenesis in transgenic mice
31. Hepatitis C core protein induces hepatocellular carcinoma in transgenic mice
32. Sensitization to Fas-mediated apoptosis by hepatitis C virus core protein
33. Suppression of apoptotic cell death by hepatic C virus core protein
34. Long lasting memory T cell responses following selflimited acute hepatitis B
35. Intracellular inactivation of the hepatitis B virus by cytotoxic lymphocytes
36. The transforming growth factor-β family
37. Transforming growth factor-β in tissue fibrosis